Contraceptive Market

Contraceptive Market Outlook for 2024 to 2034

The contraceptive market is anticipated to be valued at USD 19.79 billion in 2024 and registering a CAGR of 5.5% from 2024 to 2034. The market is foreseen to reach USD 33.79 billion by 2034.

Contraception, which involves preventing pregnancy using drugs or devices, is expanding due to factors such as family planning, higher education, health issues, and increased awareness of modern contraception.

Attributes	Details
Market Value for 2024	USD 19.79 billion
Market Value for 2034	USD 33.79 billion
Market Forecast CAGR for 2024 to 2034	5.5%

Consumption Analysis of the Contraceptive Market

• The industry's growth is predicted to be accelerated by implementing programs to reduce unwanted pregnancies and healthcare costs and increasing user awareness.
• The World Health Organization (W.H.O.) collaborates with medical partners to enhance family planning and reproductive health outcomes, improve accessibility of contraception tools, streamline programs, and mobilize global commitments.
• The development of the contraception market is driven by the need to reduce unplanned pregnancies, especially among teenage women, which is a major factor in the demand for contraception.
• The increasing population, particularly in low and middle-income countries, has led to heightened awareness about contraception methods, with the introduction of over-the-counter products fueling market development.
• The market's evolution is guided by the prevalence of unwanted pregnancies, sexually transmitted diseases, technological advancements, and awareness about sexual health, with favorable government policies influencing market growth.
• The demand for contraceptives is envisioned to expand due to increased awareness, population control efforts, and rising demand, with retail pharmacies dominating the industry due to improved supply chain networks.
• Governments are focusing more on providing timely and affordable services and increasing access to modern contraception, yet almost 214 million women globally still lack access to it. State representatives emphasize the significance of timely and affordable contraception care.

2019 to 2023 Historical Analysis vs. 2024 to 2034 Market Forecast Projection

The contraceptive market has historically developed at a CAGR of 3.9%. However, sales have advanced at a trivial pace, displaying a CAGR of 5.5% from 2024 to 2034.

Attributes	Details
Market Historical CAGR for 2019 to 2023	3.90%

Long-term use of birth control medications can cause side effects such as bleeding, headaches, nausea, and weight gain. The low adoption of contraception in developing countries is due to a lack of awareness and social taboos.

Alternative methods like condoms and IUDs, which are effective without side effects, also contribute to the low adoption rate of these drugs. Healthcare providers and facility managers face challenges integrating human rights into contraception services, ensuring high quality, autonomy, and respectful care.

The global pandemic has particularly impacted market growth, leading to a drop in device sales due to strict lockdown regulations. The family planning industry has been significantly impacted by the global pandemic, causing a slow recovery due to a lack of raw materials, workforce, and new consignments.

Clinical trials are anticipated to introduce new contraception pills and gels to address new laws and limitations on current birth control procedures. The focus is on developing a non-hormonal pill to expand men's birth control options.

Key Trends Influencing the Contraceptive Market

Widespread Demand for Wearable Pregnancy Devices

• Due to increasing awareness and changes in women's lifestyles, wearable pregnancy gadgets that use passive technology to track baby movements are becoming increasingly common.
• From home ultrasounds to infant health monitors, wearable pregnancy gadgets serve various purposes from the first day of pregnancy to childbirth, providing parents with important information.
• Due to their cost, portability, and compact size, wearable pregnancy technology is becoming increasingly popular among hospitals and home healthcare providers. It tracks the progress of the fetus.
• The WHO estimates that 800 women die from pregnancy-related illnesses every year, which is driving the market for wearable technology. Pregnancy complications are on the rise and affect both mother and child.
• Due to new care models, remote care, and the Internet of Things, wearable pregnancy gadgets are becoming prevalent, improving healthcare systems and extending maternity periods.

Adoption of Hormonal Contraception Simplifies the Pregnancy Scare

• Hormonal contraception is evolving and becoming prevalent due to the increased population and advancements in birth control technology. Hormonal pills containing estrogen and progesterone prevent pregnancy by blocking egg release, thinning the uterine lining, and thickening cervical mucus.
• Public awareness of sexual and reproductive health has led to an increased demand for hormonal contraception. Combination treatments, such as progestin and estrogen, suppress ovulation while thickening cervical mucus. These methods alter the uterine environment, making fertilization more difficult.
• Increased awareness, lifestyle changes, and government support have boosted the demand for hormonal contraception. Research and development programs aim to improve drugs and reduce side effects, with only two types currently available.
• Hormonal contraception remains a popular method for preventing pregnancy due to increased awareness, lifestyle changes, and government support programs.

Rise in Government Initiatives for Promoting Access to Family Planning

• Government initiatives promoting family planning and contraception are driving growth in the family planning market. Improved access enables individuals to make informed decisions about child spacing, leading to poverty reduction, gender equality, improved public health, and sustainable development.
• Non-profit organizations are providing funding, awareness programs, and contraception delivery in remote rural areas, escalating the reach and choices of family planning services. With support from international donors, NGOs can enhance outreach and distribution, particularly during health emergencies like global pandemics or crises of war.

Category-wise Insights

The following part offers an in-depth analysis of segments of the contraceptive market. The demand for drugs is significant, whereas the need for female contraceptive is anticipated to increase in 2024.

Contraceptive Drugs Cure up 41.50% of Market Share

Attributes	Details
Top Product Type	Drug
Market share in 2024	41.50%

The demand for contraceptive drugs is experiencing a 41.50% market share growth in 2024 due to augmented family planning and contraception efforts.

• Governments across the globe are prioritizing women's and children's health, leading to increased usage of contraceptive drugs and a significant rise in demand for these drugs, especially in emerging economies.
• The government's active involvement in promoting family planning and contraception has significantly boosted growth, empowering women and improving community health by increasing awareness and accessibility of these drugs.
• The demand for contraceptive drugs is predicted to continue rising in the coming decade as more governments and organizations invest in promoting safe and effective family planning methods.

Female Patients Develops 74.70% of Consumer Base

Attributes	Details
Top Gender	Female
Market share in 2024	74.70%

The demand for contraceptives for female patients is augmented, with a market share of 74.70% in 2024. Because female contraception techniques are more effective at preventing conception than male contraception, they are more widely used.

• The market is addressing STDs and unintended pregnancies to align with sustainable development goals, reducing maternal fatalities and promoting reproductive health. Evra and sub-dermal contraception implants cater to reproductive-age women, raising user awareness.
• Healthcare for female vitiligo patients is paramount as it impacts quality of life. Osteoporosis poses health risks, especially for postmenopausal women. Early detection and treatment are essential.
• Patient enrollment milestones indicate research progress in contraception options, including topical, diaphragm, and caps. Medications and surgery are vital for treating various health conditions.

Country-wise Insights

Based on the statistical data, industries in China and Germany are developing relatively in the upcoming decade. Simultaneously, the contraception industry in the United States and India is hitting the roof. The contraceptive sector in the ANZ region is anticipated to climb gradually in the upcoming decade.

Countries	CAGR from 2024 to 2034
United States	5.80%
Germany	5.50%
China	6.10%
India	5.80%
Australia and New Zealand	5.10%

The United States Offers a Fertile Ground for Contraception Solutions

The United States is anticipated to hold a CAGR of 5.8% from 2024 to 2034 in the contraceptive market.

In the United States, abstinence-only sex education is the primary form of sexual education, promoting abstinence from sex outside marriage or premarital sex in 39 states and the District of Columbia. However, this often excludes essential birth control measures and safe sex practices, contributing to an increase in teenage pregnancy rates due to the lack of comprehensive sex education.

Lack of accurate sex education in schools can hinder the adoption of products like female condoms, hindering market growth in the United States. Youth may remain unaware of these products, leading to their inability to use them. Therefore, it is essential to prioritize comprehensive sexual education in schools to empower young individuals to make decisions about their sexual health.

Germany Witnesses Evolving Demand for Contraceptive Devices

Demand for contraception devices in Germany is estimated to develop at a CAGR of 5.5%, with firms developing innovative solutions for birth control.

Germany's public health insurance is highly profitable, covering various health services, including birth control for women under 22. This provision ensures affordable and reliable contraception, allowing young women to make decisions about their reproductive health.

Germany's high prevalence of contraception use is attributed to its exceptional access to online information and average availability of contraception supplies, with most women using some form of birth control.

Germany achieved a 75.1 score in the 2020 European Contraception Policy Atlas, highlighting its commitment to providing comprehensive and accessible reproductive health services to its citizens.

Demand for Family Planning Awareness Skyrockets in China

China is on the brink of a significant market expansion in contraceptive devices and drugs, with a projected CAGR of 6.1% from 2024 to 2034.

Oral contraception, also known as birth control tablets or "the pill," is a popular form of contraception in China. These synthetic hormones, typically estrogen and progestin, limit ovulation and egg release, improving women's reproductive health and providing a safe and practical method of pregnancy avoidance.

China's oral contraceptives are highly effective, with less than one in 100 women experiencing unintentional pregnancy within a year of regular use, demonstrating their widespread use in the country.

China's oral contraception demand is increasing due to increased awareness, women's employment, STIs, LARC use, and Internet pharmacies.

Australia and New Zealand Cultivates Demand amidst STI Prevention Awareness

The pandemic has impacted women's access to contraception and abortion services in the ANZ region, leading to increased unintended pregnancies and a rise in contraception demand. The demand for contraception solutions in Australia and New Zealand is anticipated to register a CAGR of 5.1% through 2034.

The contraceptive market growth is primarily compelled by increasing sexually transmitted disease cases and Australia's government's and organizations' initiatives on contraception device use.

The prevalence of sexually transmitted diseases, including HIV, Gonorrhoea, Hepatitis, HPV, and PID, is predicted to boost demand for contraception devices, particularly in Australia and New Zealand.

Family Planning Applications Hits the Roof in India, Shaping Market Growth

The demand for contraception methods in India is foreseen to experience a CAGR of 5.8% from 2024 to 2034.

India's population growth boosts family planning and contraception demand, highlighting the importance of sexual and reproductive health, particularly among women, leading to increased demand for these services.

The Indian government has implemented various programs, including the National Family Planning Programme, to promote family planning and increase access to contraception methods.

Private companies are investing in contraception research and development. For instance, Reckitt Benckiser Group sold its contraception division to Mankind Pharma for USD 13 million in March 2023, providing access to various contraception, including the Durex brand.

Market Players Shaping the Outlook of the Contraceptive Market

The market is a competitive and rapidly evolving industry. Key players focus on diverse techniques to stay ahead of the competition and augment their presence in the market. Effective strategies are to acquire or collaborate with companies to improve their product portfolio and market penetration.

Companies, in addition to acquisitions and collaborations, prioritize gaining FDA approvals to ensure the safety and effectiveness of their products, giving them a competitive edge over competitors who may not have received the necessary approvals.

The leading companies are well known for their innovative products and commitment to providing safe and effective contraception to women globally. By leveraging these key strategies, they are able to stay ahead of the competition and continue to grow their businesses in a rapidly evolving market.

Recent Developments in the Contraceptive Market

• In December 2023, United Kingdom's researchers started trials for a non-hormonal male birth control pill, YCT-529, developed by Quotient Sciences. The trial involves 16 British men, aiming to shift the burden of preventing unwanted pregnancies from women to men. YCT-529 blocks access to vitamin A, preventing infertility.
• In December 2023, Aditxt acquired Evofem Biosciences, creator of the first hormone-free contraceptive gel, Phexxi, under a definitive agreement focusing on health innovations and women's health.
• In October 2023, the Indian Council of Medical Research (ICMR) completed clinical trials for the world's first injectable male contraceptive, demonstrating its safety and efficacy without serious side effects.
• In July 2023, The FDA approved Perrigo's Opill, the first nonprescription birth control pill in the United States, making it more effective than other nonprescription methods, potentially expanding access to contraception.
• In June 2023, the Biden-Harris Administration announced a public-private partnership with Upstream to improve access to contraception and address growing health disparities in the United States.
• In March 2023, NEXT Life Sciences plans to launch Plan A™, a safe, effective, and reversible male contraceptive product. The company will participate in LSI's 2023 Emerging Medtech Summit in Dana Point, California, to showcase its product and engage with investors.

Key Companies

• Bayer AG Pfizer Inc.
• Janssen Global Services, LLC
• Teva Pharmaceutical Industries Ltd.
• Merck & Co., Inc.
• Mylan N.V.
• Allergan Plc.
• Reckitt Benckiser Group plc.
• Veru Inc.
• Church & Dwight Co., Inc.
• Medisafe Distribution Inc.
• Cooper Surgical, Inc.
• Mayer Laboratories, Inc.
• Pfizer Inc.
• The Female Health Company
• Exeltis USA, Inc.

Key Coverage in the Contraceptive Market Report

• Rising Growth of the Contraceptive in the United States
• Growth Analysis of the Sexually Transmitted Infections Sector
• Top 10 Emerging Trends in Fertility and Pregnancy Rapid Test Kit Market
• Analysis of Growth Overview of Oral Contraceptive Pills Market in the United States
• Sales Assessment of Market Dynamics of At-Home Pregnancy Test Market and Family Planning Market
• Development of the United States of America Digital Pregnancy Test Kits Market

Key Segments

By Product:

• Drugs
  • Oral Contraceptive Pills
  • Injectable Contraceptive
  • Topical Contraceptive
• Devices
  • Condoms
  • Diaphragms
  • Contraceptive Sponges
  • Vaginal Rings
  • Cervical Cap
  • Subdermal Implants
  • Intra-uterine Devices
    • Copper
    • Hormonal

By Gender:

• Female
• Male

By End User:

• Institutional Sales
  • Hospitals
  • Specialty Clinics
• Retail Sales
  • Retail Pharmacy
  • Drug Stores
  • Supermarkets or Hypermarkets
• Online Sales

By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East and Africa

Frequently Asked Questions

How Big is the Contraceptive Market?

The market is valued at USD 19.79 billion in 2024.

What is the Future of the Contraceptive Market?

The market is set to be valued at USD 33.79 billion by 2034.

What is the Size of Contraception Market in the United States?

In the United States, demand for contraceptive solutions is anticipated to develop a CAGR of 5.8% by 2034.

What is the Forecast for the Contraceptive Market?

The market is to register a CAGR of 5.5% from 2024 to 2034.

How is the Demand for Top Contraceptive Product Type in 2024?

Contraceptive drugs are anticipated to acquire a 41.5% market share in 2024.